Abstract:

Objective　To investigate the expression level of PTP4A3 in patients with acute myeloid leukemia (AML) and its correlation with clinical characteristics, relapse, and prognosis. Methods　From January 2019 to December 2020, 79 patients newly diagnosed with AML who took the whole process treatment at Zhongshan People's Hospital were selected as the study objects, including 40 males and 39 females, with a median age of 58. The bone marrow samples were collected before treatment to detect the PTP4A3 expression by quantitative real-time polymerase chain reaction (qRT-PCR). The patients were divided into high- and low-expression groups based on the median PTP4A3 expression level. The relationships of PTP4A3 with the patients' age, gender, ELN risk degree, and prognosis were analyzed. The Kaplan-Meier survival analysis and Cox proportional hazards model were used to analyzed the factors influencing their prognosis. χ² test was used for the statistical analysis. Results　High PTP4A3 expression was associated with age ≥60 years (P=0.017). The relapse rate in the high-expression group was higher than that in the low-expression group [47.50% (19/40) vs. 2.56% (1/39); P<0.001]. The survival analysis revealed a median survival time of 317 d in the high-expression group. The multivariate Cox analysis indicated that age ≥60 years (HR=5.422, P=0.020) and high PTP4A3 expression (HR=4.377, P=0.027) were the independent risk factors for AML relapse. Conclusion　High PTP4A3 expression is closely linked to increased relapse risk and poor prognosis in patients with AML, suggesting its potential as an independent prognostic biomarker and therapeutic target for AML.

Key words:

Acute myeloid leukemia, PTP4A3, Prognosis

摘要：

目的　探讨PTP4A3在急性髓系白血病（AML）患者中的表达水平及其与临床特征、复发和预后的相关性。方法　2019年1月至2020年12月，选取在中山市人民医院首诊并全程治疗的79例AML患者为研究对象，其中男40例，女39例，中位年龄58岁。实时荧光定量聚合酶链式反应（qRT-PCR）检测治疗前骨髓样本中PTP4A3表达水平，以中位值为界分为高、低表达组，分析PTP4A3与患者年龄、性别、ELN危险度分层及预后的关系。采用Kaplan-Meier生存分析和Cox回归模型评估预后影响因素。采用χ²检验进行统计分析。结果　PTP4A3高表达与年龄≥60岁相关（P=0.017）。高表达组复发率高于低表达组［47.50%（19/40）比2.56%（1/39），P<0.001］。生存分析显示，高表达组中位生存时间317 d。多因素分析表明，年龄≥60岁（HR=2.31，P=0.020）和PTP4A3高表达（HR=3.05，P=0.027）是AML患者复发的独立危险因素。结论　PTP4A3高表达与AML患者高复发率和不良预后密切相关，可作为AML患者的独立预后标志物及潜在治疗靶点。

关键词:

急性髓性白血病, PTP4A3, 预后